PSMA-D5

PSMA-D5 has a binding affinity for PSMA with Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors[1]. PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

3056440-83-3

12352209

PSMA; Radionuclide-Drug Conjugates (RDCs)

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Cancer-programmed cell death

Cancer

98.61

DMSO : 50 mg/mL (ultrasonic)

OC([C@@H](NC(N[C@H](C(O)=O)CCC(O)=O)=O)CCCCNC(C1=CC(C2=CC=C(C=C2)NC(CCNC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)=CC(C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)=C1)=O)=O

C57H80N12O24

1317.31

[1]Chen Y, et al. Synthesis, Preclinical Evaluation, and First-in-Human PET Study of [68Ga]-Labeled Biphenyl-Containing PSMA Tracers. J Med Chem. 2023 Sep 28;66 (18) :13332-13345.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10781/PSMA-D5-SDS-MedChemExpress.pdf

Peptides

No Development Reported